Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous GPC3/NY-ESO-1/AFP-specific CD8-positive T lymphocytes

A preparation of autologous CD8-positive T lymphocytes that are exposed, ex vivo, to multiple specific hepatocellular carcinoma (HCC) antigens, including glypican (GPC)-3, New York esophageal squamous cell carcinoma-1 (NY-ESO-1) and alpha-fetoprotein (AFP), with potential immunostimulating and antineoplastic activities. Upon infusion of the GPC3/NY-ESO-1/AFP-specific CD8-positive T lymphocytes, the T cells specifically target and lyse cells expressing the targeted HCC neoantigens.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous HCC antigens-specific CD8-positive T lymphocytes
autologous HCC antigens-specific CD8+ T lymphocytes
autologous specific HCC antigens CD8+ T cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search